MTOR and hematologic disorder: For instance activating mutations in FLT3, NRAS, KRAS, KIT, the regulatory subunit of PI3K, or loss-of-function mutations of PTEN, can affect this pathway.3, 21, 22 Recently, we have shown that, in addition to mutations in these genes, activation of other downstream kinases, such as SYK and p110, contribute to hematopoietic malignancies by activating the PI3K/mTOR pathway.23, 24 Several PI3K/mTOR inhibitors have been used in the treatment of solid tumors and hematological malignancies.